PriceTargets.com logo

Revance Therapeutics - RVNC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.96
  • Forecasted Upside: 189.88%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.09 As of 12/20/2024 06:31 PM ET
▲ +0.02 (0.65%)

This chart shows the closing price for RVNC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Revance Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVNC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVNC

Analyst Price Target is $8.96
▲ +189.88% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Revance Therapeutics in the last 3 months. The average price target is $8.96, with a high forecast of $20.00 and a low forecast of $3.10. The average price target represents a 189.88% upside from the last price of $3.09.

This chart shows the closing price for RVNC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in Revance Therapeutics. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2024MizuhoLower TargetNeutral ➝ Neutral$6.66 ➝ $3.10
11/8/2024Needham & Company LLCReiterated RatingHold
11/8/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$6.60 ➝ $6.60
10/28/2024Needham & Company LLCReiterated RatingHold
9/13/2024BarclaysReiterated RatingOverweight ➝ Equal Weight$10.00 ➝ $7.00
8/13/2024Needham & Company LLCDowngradeModerate Buy ➝ Hold
8/13/2024HC WainwrightDowngradeStrong-Buy ➝ Hold
8/12/2024Piper SandlerDowngradeStrong-Buy ➝ Hold
8/12/2024GuggenheimReiterated RatingBuy ➝ Neutral
8/12/2024William BlairReiterated RatingOutperform ➝ Market Perform
8/9/2024Piper SandlerLower TargetOverweight ➝ Overweight$11.00 ➝ $6.00
8/9/2024Stifel NicolausLower TargetBuy ➝ Buy$24.00 ➝ $20.00
8/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $11.00
5/13/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$9.00 ➝ $8.00
5/10/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$20.00 ➝ $11.00
5/10/2024Needham & Company LLCLower TargetBuy ➝ Buy$18.00 ➝ $12.00
5/10/2024MizuhoLower TargetNeutral ➝ Neutral$9.00 ➝ $8.00
3/1/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$8.00 ➝ $9.00
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
2/29/2024Needham & Company LLCLower TargetBuy ➝ Buy$20.00 ➝ $18.00
2/29/2024Piper SandlerLower TargetOverweight ➝ Overweight$42.00 ➝ $20.00
2/23/2024HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $12.00
1/29/2024BarclaysLower TargetOverweight ➝ Overweight$35.00 ➝ $10.00
1/29/2024MizuhoDowngradeBuy ➝ Neutral$16.00 ➝ $9.00
1/9/2024Needham & Company LLCLower TargetBuy ➝ Buy$25.00 ➝ $20.00
1/9/2024The Goldman Sachs GroupDowngradeBuy ➝ Neutral$30.00 ➝ $8.00
11/22/2023MizuhoLower TargetBuy ➝ Buy$35.00 ➝ $16.00
11/9/2023Piper SandlerLower TargetOverweight ➝ Overweight$44.00 ➝ $42.00
11/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$35.00 ➝ $25.00
11/6/2023HC WainwrightLower TargetBuy ➝ Buy$41.00 ➝ $15.00
10/23/2023BarclaysLower TargetOverweight ➝ Overweight$40.00 ➝ $35.00
10/11/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$25.00 ➝ $12.00
9/20/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$38.00 ➝ $33.00
9/20/2023Needham & Company LLCLower TargetBuy ➝ Buy$40.00 ➝ $35.00
9/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$41.00
9/20/2023Piper SandlerLower TargetOverweight ➝ Overweight$50.00 ➝ $44.00
8/16/2023BNP ParibasUpgradeUnderperform ➝ Neutral$20.00
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$41.00
8/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$26.00 ➝ $25.00
8/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$44.00 ➝ $40.00
8/9/2023HC WainwrightLower TargetBuy ➝ Buy$48.00 ➝ $41.00
6/7/2023MizuhoBoost Target$33.00 ➝ $35.00
5/10/2023Piper SandlerBoost Target$39.00 ➝ $50.00
5/10/2023HC WainwrightBoost Target$42.00 ➝ $48.00
4/19/2023Needham & Company LLCReiterated RatingBuy$40.00
4/11/2023HC WainwrightReiterated RatingBuy$42.00
3/15/2023MizuhoBoost Target$30.00 ➝ $33.00
3/14/2023Wells Fargo & CompanyBoost Target$22.00 ➝ $30.00
3/1/2023HC WainwrightReiterated RatingBuy$42.00
3/1/2023Needham & Company LLCBoost TargetBuy$38.00 ➝ $40.00
3/1/2023BarclaysBoost TargetOverweight$37.00 ➝ $40.00
1/31/2023Piper SandlerBoost TargetOverweight$29.00 ➝ $40.00
1/26/2023HC WainwrightBoost TargetBuy$29.00 ➝ $42.00
1/24/2023Morgan StanleyBoost TargetEqual Weight$25.00 ➝ $26.00
1/10/2023Needham & Company LLCBoost TargetBuy$35.00 ➝ $38.00
11/16/2022BarclaysBoost TargetOverweight$35.00 ➝ $37.00
11/15/2022GuggenheimBoost Target$36.00
11/9/2022Morgan StanleyLower TargetEqual Weight$27.00 ➝ $25.00
10/11/2022Morgan StanleyInitiated CoverageEqual Weight$27.00
9/22/2022The Goldman Sachs GroupInitiated CoverageBuy$33.00
9/9/2022MizuhoBoost TargetBuy$26.00 ➝ $30.00
9/9/2022BarclaysBoost TargetOverweight$22.00 ➝ $35.00
9/9/2022HC WainwrightBoost TargetBuy$25.00 ➝ $29.00
9/8/2022Needham & Company LLCBoost TargetBuy$25.00 ➝ $35.00
9/8/2022CowenBoost Target$55.00 ➝ $65.00
9/8/2022CowenBoost Target$55.00 ➝ $65.00
8/25/2022Wells Fargo & CompanyBoost TargetEqual Weight$17.00 ➝ $24.00
8/15/2022GuggenheimBoost Target$35.00
8/10/2022HC WainwrightBoost Target$20.00 ➝ $25.00
1/19/2022HC WainwrightReiterated RatingBuy$18.00
10/26/2021BarclaysLower TargetOverweight$33.00 ➝ $22.00
10/25/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$35.00 ➝ $17.00
10/18/2021Needham & Company LLCLower TargetBuy$45.00 ➝ $25.00
10/13/2021MizuhoReiterated RatingBuy$36.00
10/13/2021HC WainwrightReiterated RatingBuy$35.00 ➝ $26.00
8/6/2021BarclaysBoost TargetOverweight$32.00 ➝ $33.00
5/11/2021MizuhoLower TargetBuy$37.00 ➝ $36.00
4/23/2021MizuhoBoost TargetBuy$33.00 ➝ $37.00
4/14/2021Needham & Company LLCReiterated RatingBuy$45.00
2/23/2021MizuhoBoost TargetPositive ➝ Buy$30.00 ➝ $33.00
2/23/2021HC WainwrightBoost TargetBuy$33.00 ➝ $35.00
1/8/2021Needham & Company LLCBoost TargetBuy$42.00 ➝ $45.00
11/10/2020MizuhoLower TargetBuy$32.00 ➝ $30.00
10/26/2020BarclaysBoost TargetOverweight$35.00 ➝ $38.00
10/15/2020Needham & Company LLCBoost TargetBuy$36.00 ➝ $42.00
10/15/2020HC WainwrightBoost TargetBuy$27.00 ➝ $33.00
9/28/2020BarclaysBoost TargetOverweight$32.00 ➝ $35.00
8/11/2020MizuhoInitiated CoverageBuy$32.00
7/10/2020HC WainwrightReiterated RatingBuy$27.00
6/2/2020HC WainwrightReiterated RatingBuy$24.00
5/20/2020MizuhoReiterated RatingBuy$35.00
4/16/2020Stifel NicolausLower TargetBuy$35.00 ➝ $31.00
4/15/2020Needham & Company LLCReiterated RatingBuy$36.00
4/1/2020MizuhoReiterated RatingBuy$39.00 ➝ $35.00
3/27/2020William BlairReiterated RatingBuy
3/27/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $24.00
3/22/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$32.00 ➝ $15.00
2/26/2020HC WainwrightReiterated RatingBuy$23.00 ➝ $28.00
2/25/2020Piper SandlerBoost TargetOverweight$37.00 ➝ $40.00
2/25/2020Needham & Company LLCBoost TargetBuy$32.00 ➝ $36.00
2/18/2020Piper SandlerLower TargetOverweight$38.00 ➝ $37.00
1/23/2020MizuhoBoost TargetBuy ➝ Positive$34.00 ➝ $39.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 8 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 5 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 7 very positive mentions
  • 17 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 7 very positive mentions
  • 17 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Revance Therapeutics logo
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $3.09
Low: $3.07
High: $3.09

50 Day Range

MA: $4.34
Low: $3.03
High: $5.92

52 Week Range

Now: $3.09
Low: $2.30
High: $9.74

Volume

3,458,729 shs

Average Volume

2,819,810 shs

Market Capitalization

$322.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Revance Therapeutics?

The following Wall Street sell-side analysts have issued reports on Revance Therapeutics in the last year: Barclays PLC, Guggenheim, HC Wainwright, Mizuho, Needham & Company LLC, Piper Sandler, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for RVNC.

What is the current price target for Revance Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Revance Therapeutics in the last year. Their average twelve-month price target is $8.96, suggesting a possible upside of 189.9%. Stifel Nicolaus has the highest price target set, predicting RVNC will reach $20.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $3.10 for Revance Therapeutics in the next year.
View the latest price targets for RVNC.

What is the current consensus analyst rating for Revance Therapeutics?

Revance Therapeutics currently has 8 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RVNC, but not buy more shares or sell existing shares.
View the latest ratings for RVNC.

What other companies compete with Revance Therapeutics?

Other companies that are similar to Revance Therapeutics include Day One Biopharmaceuticals, Ardelyx, Spyre Therapeutics, Calliditas Therapeutics AB (publ) and ARS Pharmaceuticals. Learn More about companies similar to Revance Therapeutics.

How do I contact Revance Therapeutics' investor relations team?

Revance Therapeutics' physical mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company's listed phone number is (615) 724-7755 and its investor relations email address is [email protected]. The official website for Revance Therapeutics is www.revance.com. Learn More about contacing Revance Therapeutics investor relations.